Ask AI

Integrating Bispecific Antibody Therapy for Multiple Myeloma Into Your Community Practice: Case Studies and Expert Guidance

Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 31, 2026

Expiration: February 28, 2027

See Activity Collection

This activity outlines how healthcare professionals can make changes to their practice site’s systems and establish workflows that are required for community centers to fully integrate BsAb therapy into their care of patients with multiple myeloma. Preparation and resources are needed to identify eligible patients and safely administer BsAb therapy. Education is necessary for healthcare professionals to understand how to manage the adverse effects possible with BsAbs, and pharmacies are required to establish a REMS program.

MM BsAb in Community Practice

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with MM do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

You have managed a patient with relapsed/refractory (R/R) multiple myeloma (MM) for 9 years who has previously received multiple lines of therapy and is progressing. You are evaluating whether the patient is a good candidate to receive a bispecific antibody (BsAb) for MM. Which barrier would prevent the patient from being eligible for treatment with BsAb therapy during the step-up dosing?

4.

For a community-based cancer center to successfully administer BsAbs in their patients with R/R MM, several processes need to be in place before being able to deliver this treatment. What is the first step toward integrating BsAbs?